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Abstract
Background: Current guidelines for the provision of protein for critically ill patients are based on incomplete
evidence, due to limited data from randomised controlled trials. The present pilot randomised controlled trial is
part of a program of work to expand knowledge about the clinical effects of protein delivery to critically ill
patients. The primary aim of this pilot study is to determine whether an enteral feeding protocol using a
volume target, with additional protein supplementation, delivers a greater amount of protein and energy to
mechanically ventilated critically ill patients than a standard nutrition protocol. The secondary aims are to
evaluate the potential effects of this feeding strategy on muscle mass and other patient-centred outcomes.
Methods: This prospective, single-centred, pilot, randomised control trial will include 60 participants who
are mechanically ventilated and can be enterally fed. Following informed consent, the participants receiving
enteral nutrition in the intensive care unit (ICU) will be allocated using a randomisation algorithm in a 1:1 ratio to
the intervention (high-protein daily volume-based feeding protocol, providing 25 kcal/kg and 1.5 g/kg protein) or
standard care (hourly rate-based feeding protocol providing 25 kcal/kg and 1 g/kg protein). The co-primary
outcomes are the average daily protein and energy delivered to the end of day 15 following randomisation.
The secondary outcomes include change in quadriceps muscle layer thickness (QMLT) from baseline (prior to
randomisation) to ICU discharge and other nutritional and patient-centred outcomes.
Discussion: This trial aims to examine whether a volume-based feeding protocol with supplemental protein
increases protein and energy delivery. The potential effect of such increases on muscle mass loss will be
explored. These outcomes will assist in formulating larger randomised control trials to assess mortality and
morbidity.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN: 12615000876594 UTN:
U1111-1172-8563.
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Background
Nutritional therapy, preferably via the enteral route,
is part of the standard care for critically ill patients
[1]. Prominent critical care nutrition guidelines rec-
ommend that protein should be provided at a level
of 1.2–2.0 g/kg/day, with possibly higher amounts
for patients with multi-trauma, obesity and burns
and greater than 80% of energy targets should be
met [1]; however, there is a lack of high-quality evi-
dence to support these guidelines [2]. Despite these
and similar guidelines, nutritional delivery in the in-
tensive care unit (ICU) is frequently less than these
targets; observational data from a large international
dataset suggests that critically ill patients only re-
ceive, mean SD, 43 g ± 27 of protein and 1054 kcal ±
717 of energy per day, which equates to approxi-
mately 50 and 60% of their protein and energy tar-
gets, respectively [3]. More recent observational data
from this dataset suggests that increasing protein de-
livery by 30 g, or meeting greater than 80% of pre-
scribed protein targets, is associated with greater
survival, an increase in ventilator-free days and a
shorter time to discharge alive from the ICU [4, 5].
In addition, data from a prospective observational
cohort study from a single centre suggested that the
provision of more protein (greater than 1.5 g/kg/day)
was associated with a reduction in mortality when
adjusted for severity of illness and age [6]. Finally,
observational study and preliminary trial data sup-
porting the concept that increasing calorie delivery
will improve outcomes [7–9].
Standard enteral feeding regimens are generally
based on an hourly target rate of administration of a
selected formulation, calculated according to daily
energy and protein targets [10]. Therefore, if inter-
ruptions to feed delivery occur, protein and energy
targets are not met [11]. Furthermore, protein deliv-
ery is generally restricted by the composition of the
enteral formula available because overall energy re-
quirements mostly determine the volume of the for-
mula prescribed. In a cluster randomised control
trial, Heyland and colleagues reported that with a
novel approach to feeding, including a volume-based
feeding protocol, delivery of protein increased by
14% (95% CI, 5–23%) and calories by 12% (95% CI,
5–20%) [11]. However, theoretically, volume-based
feeding protocols with protein supplementation may
not achieve greater delivery of protein and energy to
patients due to issues with feeding intolerance, as in-
creased nutrient delivery, particularly protein, to the
small intestine, stimulates the feedback loop to slow
gastric emptying [12, 13]. Therefore, this approach
may inadvertently decrease protein and energy
delivery.
Beyond mortality, patient-centred functional out-
comes in survivors of critical illness are increasingly
being recognised as important variables that may be
influenced by nutrition [14, 15]. This includes
muscle weakness, which is often described as Inten-
sive Care Unit Acquired Weakness (ICUAW) [16].
Lower health-related quality of life (HRQoL) scores
are associated with ICUAW, emphasising that weak-
ness is important to patients [17–19]. The loss of
skeletal muscle has been identified as a crucial con-
tributing factor to the development of ICUAW [20,
21], with ultrasound being a potentially useful and
minimally invasive modality to quantify muscle mass
and muscle loss in the critically ill [22–24].
Augmenting nutrient delivery, particularly in-
creased protein delivery, has been proposed as an
approach that may attenuate muscle loss associated
with critical illness. At present, there is an absence
of robust data to support this approach [25] and re-
cent studies have reported conflicting conclusions
[6]. Most recently, Ferrie and colleagues [26] per-
formed a randomised controlled trial in parenterally
fed patients. Amongst other outcomes, they mea-
sured muscle mass and strength [26]. This study of
119 critically ill patients, who were randomised to
receive a target of either 0.8 or 1.2 g/kg protein per
day with isocaloric parenteral nutrition, did not find
strong evidence of a difference in the primary out-
come of handgrip strength at day 7, but the ob-
served point estimate was in the direction of benefit
for those receiving greater protein delivery. More-
over, the augmented protein intervention may have
been associated with reduced fatigue and greater
forearm muscle thickness using ultrasound [26]. A
retrospective observational study of 106 critically ill
patients, by Ishibashi and colleagues, reported that
protein intake above 1.5 g/kg/day substantially re-
duced total body protein loss when compared to
those who receive less than 1.1 g/kg/day [27]. In
contrast, Casaer and colleagues reported that greater
calorie and protein administration, particularly when
delivered via the parenteral route, reduced the quan-
tity and quality of muscle and was associated with
greater muscle weakness [28]. This negative signal
was also described by Puthucheary and colleagues,
who reported greater muscle wasting associated with
increased protein delivery [29].
At present, there is conflicting evidence around
the optimal protein provision to critically ill patients
including a lack of high-quality evidence which in-
cludes patient-centred functional outcomes. This
single-centre pilot trial in mechanically ventilated
critically ill patients is part of a program to explore
the influence of protein prescription on outcomes;
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aims to determine whether a volume-based enteral
feeding protocol with additional protein supplemen-
tation delivers a greater amount of protein and
energy than a standard nutrition protocol.
Study objectives
Co-primary
The primary aim of this pilot study is to determine
whether a volume-based feeding protocol with supple-
mental protein potentially improves the average daily pro-
tein and energy delivery, when compared to standard care
in mechanically ventilated critically ill patients.
Secondary
The secondary aims are to evaluate whether a volume-
based feeding protocol with supplemental protein when
compared to standard care:
I. Improves overall protein and energy adequacy
without increasing feeding intolerance or
diarrhoea.
II. Improves nutritional-related outcomes including
the incidence of malnutrition at ICU discharge
or mid upper arm circumference change from
baseline to discharge.
III.Decreases the change in quadriceps muscle layer
thickness (QMLT) from baseline to ICU
discharge.
IV.Decreases the incidence of ICUAW or alters
muscle strength or physical function scores at
ICU discharge.
V. Alters the duration of the ICU admission,
number of deaths, and the requirement for
discharge to a rehabilitation facility.
Methods/design
This pilot, single-centred, single-blinded, parallel
group, prospective randomised controlled trial has
been designed in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT 2013) [30] and the Consolidated Stan-
dards for Reporting of Trials CONSORT guidelines
[31] (Fig. 1, study flow diagram. The study will be
undertaken at the Royal Melbourne Hospital ICU,
which is a university-affiliated, tertiary referral,
Fig. 1 Study flow diagram: flow diagram of patients recruited and study conduct. Abbreviations: MV mechanically ventilated, LOMT limit
of medical treatment, yo years old, FEED Protocol intervention
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mixed medical-surgical-trauma ICU with 32-beds
that has > 2500 patients admitted per year.
Study participants
Sixty patients will be recruited within 48 h of their
index ICU admission. Screening commenced on 10th
of August 2015 and is performed only on weekdays.
Patients who meet the study criteria (Table 1.) will
be eligible to participate. As all eligible patients are
mechanically ventilated and unable to consent to
participation, informed consent will be obtained
from the person responsible as per local laws. Con-
sent to continue in the trial will be obtained from
the participant if they recover adequately and they
are deemed competent. The protocol and consent
process has been approved by the Royal Melbourne
Hospital Human Research Ethics Committee
(2015.048). The protocol is registered with Austra-
lian New Zealand Clinical Trials Registry (ANZCTR;
U1111-1172-85630).
Baseline data collection
Baseline measurements will reflect the status of pa-
tients at or prior to randomisation. Demographic
data includes admission diagnosis, comorbid illness
including quantification using the Charlson Comor-
bidity Index [32], Katz Activities of Daily Living
(ADL) index [33] (prior to the ICU admission),
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score, and admission Sequential Organ
Failure Assessment (SOFA) Score. Baseline measures,
collected by the study Dietitian, include height
(using ulna length [34]), weight (from bed scales),
body mass index (BMI), mid upper arm circumfer-
ence, nutritional status using the subjective global
assessment (SGA) [35, 36], plasma albumin, highest
and lowest blood glucose in the first 24 h of ICU
admission, independent dietitian estimation of energy
(weight-based or Schofield equation [37]) and pro-
tein requirements and the first quadriceps muscle
layer thickness measure [24], see Table 3 for details
of data collection.
Randomisation and blinding
We will use a simple randomisation system to assign
participants [1:1] to receive either standard care or
the intervention. Allocation will be concealed using
sequentially numbered opaque sealed envelopes, held
by research personal not involved with the study. If
the participant or the person responsible wishes to
withdraw consent at any time, all study procedures
will cease and the participant will receive standard
ICU care as directed by the clinical team. Due to
the nature of the intervention, the study is single-
blinded. However, outcomes of muscle strength and
physical function will be measured by an investigator
blinded to the group allocation. Data analysis will be
performed using a binary treatment code to maintain
group allocation of blinding until the results are
finalised.
Trial intervention and comparator
The intervention or standard care will be delivered
following randomisation until ICU discharge; the
patient no longer requires enteral tube feeding, or at
the end of day 15, with the day of randomisation be-
ing day 1. Tolerance of enteral nutrition will be
assessed and managed similarly for both groups, with
prokinetic drugs (metoclopramide 10 mg q.i.d. and
erythromycin 200 mg b.d.) administered if gastric
residue volumes at any time equal or exceed 300 ml
[38]. The need for parenteral nutrition will be deter-
mined by treating clinical staff that are not investiga-
tors and are not aware of group allocations.
Standard care group
The comparator group will receive standard nutri-
tion care [39], which includes commencing a stand-
ard commercially available 1.0 kcal/ml enteral
formula (Nutrison® 1.0 kcal, Nutricia, Wuxi, China),
providing 40 g protein and 1000 kcal per litre.
Liquid nutrient will be commenced using our ICU
nutrition protocol (Appendix), and the target rate
will be set at 25 kcal/kg ideal body weight (IBW)
[1]. This strategy is designed to prescribe 1.0 g/kg
protein and 25 kcal/kg of energy per day, however it
is anticipated participants will receive less than this
due to interruptions to nutrition therapy [39]. For
participants below or within the IBW range (defined
as a BMI between 18.5–25 kg/m2 for 18–65 years
Table 1 Inclusion and exclusion criteria
Inclusion • Adults, ≥ 18 years of age
• Mechanically ventilated (MV) for ≥ 48 h with no immediate plans to extubate in the next 24 h
Exclusion • Patients who have a contraindication to enteral feeding
• Limit of medical treatment order in place or imminent death
• Pre-morbid disability causing inability to ambulate > 10 m independently (+/− gait aid)
• Pregnancy
• The treating clinician considers the intervention not in the patients best interest or too burdensome
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and 22–27 kg/m2 for ≥ 65 years [40]), actual body
weight will be used. For participants with BMI ≥
32 kg/m2, an adjusted IBW will be used (IBW + 25%
(actual weight – IBW)) [41].
Intervention group
The intervention group will receive their nutrition care
based on the FEED protocol (Fig. 2, FEED protocol). It
is anticipated that this will provide 1.5 g/kg protein and
25 kcal/kg of energy per day. The enteral formula will be
a 1.25 kcal/ml formula (Nutrison® Protein plus, Nutricia,
Zoetermeer, The Netherlands), providing 1250 kcal
and 63 g protein per litre. The target formula volume
will be determined based on 25 kcal/kg IBW, and the
difference between the protein provided from the en-
teral formula and the target protein requirement of
1.5 g/kg IBW will be calculated. This difference will
be met using protein powder (Beneprotein®, Nestle
Health Sciences, Switzerland), provided in 6 g protein
boluses (1 scoop of powder (7 g), provides 6 g of
protein) over the day. Beneprotein® is a commercially
available product that contains 100% whey protein
isolate. To ensure that the target volume of formula
is delivered, at 16:00 each day, the ICU bedside nurse
will calculate the volume of formula provided,
compared to the target volume, and then adjust the
feed rate to aim to deliver the remaining feed volume
over the 8-h period to midnight, with a maximum
feeding rate of 150 ml/h [11]. The data on compli-
ance to the feeding protocol will be collected.
Management of fluid overload
For both groups, if the attending intensivist wishes
to reduce the volume of feed provided, the feed will
be changed to Nutrison® Concentrate 2.0 kcal/ml,
(Nutricia, Zoetermeer, The Netherlands) with a goal
to provide 25 kcal/kg of energy. For the standard
care group, this will mean they will receive compar-
able protein delivery to the 1.0 kcal formula. For the
intervention group, the protein supplementation will
be increased in an attempt to achieve 1.5 g/kg/day.
These changes will be recorded.
Management of withdrawal
Stopping criteria are provided (Table 2), and any
withdrawals will be recorded. The data will be
retained and reported for all withdrawals where
allowed by patient consent. Any adverse events will
be recorded and reported.
Calculate Target Volume of a Protein Plus 
based on 25kcal/kg IBW 
Set hourly feed Target Rate (TR) for volume to 
be delivered over 24 hours (Target Volume/24) 
Protein target calculated 
1.5g/kg/day IBW 
Calculated protein provided 
by the Target Volume of 
feed 
Prescribe Beneprotein® 
flushes to meet requirements 
(7g in 60ml H2O) 
At 16:00 each day nursing 
staff assess volume of feed 
remaining to be delivered 
until midnight 
Target volume – volume delivered 
= remaining volume / 8 hours = 
new TR (maximum of 150ml/hr) 
until midnight 
At midnight return to 




Fig. 2 FEED protocol: how nutrition will be delivered in the intervention group. Abbreviations: kg kilogramme, IBW ideal body weight, g gram, ml
millilitre, H20 water
Table 2 Criteria for withdrawal
Criteria Measure
Feed intolerance Tolerating < 40% of requirements via the enteral route for ≥ 3 days
Renal failure If eGFR is < 25% and the patient is not commenced on continuous
renal replacement therapy within 2 days
Severe oedema > 5 L positive fluid balance, without alternative way to manage fluid
balance and attending physician assesses the feed volume and
additional protein to be impacting on the patients treatment after the
above volume considerations have been implemented
Diarrhoea ≥ 500 ml per day or five bowel actions
Intensivist or attending physician request No parameter
Participant/person responsible request to withdraw No parameter
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Management of adverse events
It is not expected that any adverse events will occur
in relation to the study protocol. However, each par-
ticipant will be monitored regularly by study
personnel for adverse events occurring throughout
the study. If any adverse events do present the na-
ture, severity, causality, and course of the adverse
event will be recorded. Adverse events such as
death, ischaemic bowel, renal failure, and diarrhoea
will be recorded from the time of consent; if these
events occur, this will be discussed with the attend-
ing ICU consultant to determine if they may be re-
lated to the study. Any severe adverse events related
to the study will be reported to the Melbourne
Health Human Research and Ethics Committee
within 24 h of personnel becoming aware of it.
Outcome measures
The data collection and the outcome measures are
summarised in Fig. 3.
Primary outcomes
The co-primary outcomes are mean daily protein
and energy provided over the 15-day study period.
The provision of protein and energy will be calcu-
lated on a daily basis and will be determined taking
into account all sources; this includes nutrition ther-
apy (enteral formula, protein supplements, and
Fig. 3 Study events, data collection, and outcome measures. *Baseline data includes age, gender, body mass index, admission diagnosis, Charlson
Comorbidity Index, APACHE II score, SOFA Score, Katz Activities of Daily living (ADL) index, dietitian estimation of energy, and protein requirements. **Daily
ICU data includes interruptions to feeding, fluid balance, feeding intolerance (gastric residual volumes), diarrhoea (> 300 ml per day), the presence of sepsis,
renal failure, urea and creatinine levels, blood sugar levels and insulin dose (unit/day). Abbreviations: FEED protocol intervention, ICU intensive care unit,
QMLT quadriceps muscle layer thickness, SGA subjective globe assessment, MUAC mid upper arm circumference, LOS length of stay, MV mechanical
ventilation, D/C discharge
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parenteral formula), dextrose, and propofol. The
mean protein and energy provided will be deter-
mined, by adding the daily provision over the 15-day
study period (the 14 complete calendar days). The
provision of any nutrition prior to commencing the
study protocol will be collected and reported but not
included in the primary outcome analysis.
Secondary outcomes
The first secondary outcome measurement is the
change in muscle mass, determined as the change in
QMLT using ultrasound from baseline to day 15 or
ICU discharge if earlier. A portable ultrasound de-
vice (Sonosite S-ICU™) with a multiple frequency
transducer (13-6 MHz, 6 cm) will be used to obtain
muscle mass images. The method to obtain the im-
ages will be carried out as described by Tillquist and
colleagues [24], with measurements completed using
both minimal and maximal pressures. The first
measure will be taken before randomisation, then on
day 5, day 10, and at discharge or day 15 of ICU. A
single-trained operator will complete all QMLT mea-
sures, and this technique has a very good intrarater
reliability in both healthy populations [24] and critic-
ally ill patients [42]. The measurement will be com-
pleted on all participants, with bilateral
measurements at two points; the midpoint between
the Anterior Superior Iliac Spine (ASIS) and the
upper pole of the patella and at the point two thirds
between the ASIS and the top of the patella [22–24],
the landmarks will be marked using a permanent
pen. A linear measure will be taken for each point
twice, with minimal pressure and maximal pressure ap-
plied and the measures will be recorded [22]. The device
settings will be standardised for each measure, and bony
landmarks will be used to determine if the transducer is
oriented perpendicular to the muscle [24]. Each image will
be stored to the hard drive of the ultrasound device and
then transferred for further blinded analysis at a later date.
The change in QMLT from baseline to day 5 and dis-
charge or day 15 will be calculated for each patient for the
measurements taken with minimal pressure and maximal
pressure separately.
The other secondary outcomes are total calorie
and protein provision, calorie deficit and protein ad-
equacy, incidence of feed intolerance, number of
days of feed intolerance, incidence of diarrhoea de-
fined as more than three bowel actions or greater
than 300 ml per day [43], length of ICU stay, hos-
pital mortality at 28 and 60 days, discharge destin-
ation, muscle strength, the incidence of ICU AW
and physical function at ICU discharge, and the
change in nutritional markers over the study period.
Nutritional markers include assessment of
malnutrition using the Subjective Globe Assessment
(SGA) [35], mid upper arm circumference (MUAC),
and body weight. These measures will be carried out
at baseline, day 5, and at discharge from ICU; the
change from baseline to discharge or day 15 will be
calculated. The presence of acute renal failure de-
fined by the RIFLE criteria [44] and plasma urea and
creatinine levels will be assessed on a daily basis.
Protein adequacy will be determined over the ICU
admission or until day 15 by adding the daily pro-
tein provision and comparing this to the estimated
protein requirements determined by the dietitian.
The protein adequacy will then be explored in rela-
tion to the other outcome measures.
Calorie deficit will be determined using both pre-
dicted weight-based energy requirements (25 kcal/
kg). In eligible patients, calorie deficit will also be
calculated using measured energy expenditure (MEE)
[45]. Cumulative calorie deficit will be calculated
over the ICU admission or until day 15 of the study.
MEE will be assessed with indirect calorimetry using
E-sCOVX (GE, Helsinki, Finland) [46]. The first
MEE will be within 24 h of enrolment into the study
and repeated on day 3, day 5, and day 7 of the ICU
stay. The measurements will be carried out with the
patient in a fed state lying supine. The measure will
be taken over a 2-h period, and the summary data of
respiratory quotient (RQ) and MEE will be recorded.
The feeding rates will not be adjusted in relation to
the MEE [47]. Contraindications to carrying out a
metabolic measurement will include if the patient is
on continuous renal replacement therapy or extra-
corporeal membrane oxygenation (ECMO) or if the
patient has an intercostal catheter with an air leak
or is on a fraction of inspired oxygen greater than
0.6 [47].
Feed intolerance will be determined as a single
gastric residual volume > 300 ml [48].
Muscle strength will be determined in suitable par-
ticipants using handgrip dynamometry and the Med-
ical Research Council (MRC) scale [49, 50]. The first
muscle strength test will be performed at awakening
[50] and then again at discharge or day 15, which-
ever comes first. Patients will be screened for atten-
tion and comprehension on the basis of their ability
to follow commands, they will be considered awake
if they score at least three out of five using the De
jonghe comprehension criteria on at least two occa-
sions within a 6-h period [51] and have a Riker
sedation-agitation scale score of three to five [52].
Handgrip dynamometry (Commander Echo™ Wireless
Grip Dynamometer, USA) will be measured in both
limbs with the participant in a chair or sitting at
least at 45° in bed, with the patients elbow at 90°
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supported by a pillow or the arm of the chair. The
Medical Research Council sum score (MRC-SS) will
be measured as previously described [51, 53, 54]
with ICUAW defined as an MRC-SS of < 48/60 [55].
Physical function will also be assessed using the
physical function in Intensive Care Test–scored
(PFIT-s) [56, 57]. Patients may only be able to perform
part of the test, but are still able to obtain a score.
Sample size
A sample size of 60 is based on observational data
[45], where daily protein intake, mean (SD), was
50.8 g (20.1 g) protein per day; therefore, 29 partici-
pants per group will provide 80% power (two-sided
α 0.05) to detect a minimum difference of a 15-g
protein between groups. While there is limited data
on change in muscle mass using ultrasound, using
the data from the VALIDUM study, mean (SD)
QMLT of 1.3 (0.6) cm [22], a sample size of 28 par-
ticipants in each group will also provide over 80%
power to detect a mean difference of 0.5 cm in
QMLT.
Statistical analysis
All analyses will use an intention-to-treat approach.
Baseline patient demographics, severity of illness,
ICU length of stay, mortality, and nutritional
markers will be tabulated according to the treatment
group. Initial exploratory data analysis will involve
calculation of summary statistics and comparison be-
tween treatment groups using non-parametric (Wil-
coxon), parametric (t test), and Fisher’s exact tests as
appropriate, as well as construction of trajectory
plots according to the treatment group. The co-
primary outcomes of average daily energy and pro-
tein delivery will be compared between treatment
and control groups with two-sample unpaired t tests,
with statistical significance for each set conserva-
tively at two-sided values of 0.025 to limit the
family-wise type 1 error for the two co-primary out-
comes to less than 0.05 overall.
All secondary outcomes will be regarded as ex-
ploratory and hypothesis-generating, with no mul-
tiple comparison adjustment to conventional 5% type
1 error thresholds. Group differences for change
from baseline at selected time points in continuous
outcome variables, including QMLT, will be com-
pared after adjustment for initial values using ana-
lysis of covariance (ANCOVA) regression models,
initially unadjusted, and subsequently adjusted as de-
scribed below for other regression models. Natural
logarithmic transformations may be applied to stabil-
ise variance within these or other linear models if
appropriate. The relationships between calorie
deficits using both prescribed calories (25 kcal/kg)
and MEE and protein adequacy and the outcome
measures (QMLT change, muscle strength, diagnosis
of ICUAW, and physical function at ICU discharge)
will be explored using linear or logistic regression
analyses, with adjustment for likely confounders and
any baseline variable found to show substantial im-
balance between treatment groups. Finally, a
population-averaged generalised linear model using a
generalised estimating equation (GEE) approach with
an unstructured working correlation matrix and ro-
bust standard error estimates adjusted for clustering
within individual subjects will be applied to these
longitudinal data to evaluate the overall associations
of the vector of (untransformed or log transformed)
outcome variables with treatment group across mul-
tiple time points. Multiple imputations for missing
data may be used to support conclusions from other
generalised linear models constructed without imput-
ation of missing data. Data analysis will be carried
out using the Statistical Package for the Social Sci-
ences (SPSS) (IBM® SPSS® Statistics Premium Grad
Pack Version 22.0) or Stata Corporation (Stata Stat-
istical Software: Release 15. College Station, TX: Sta-
taCorp LP; 2017).
Discussion
It has been hypothesised that protein provision may
be more important than energy provision for critic-
ally ill patients [25]. Optimal protein delivery may
also influence functional outcomes via attenuation of
muscle loss. However, the optimal amount of enteral
protein required in critical illness is relatively un-
known and has not been rigorously studied. More-
over, attempts to augment enteral protein delivery
may result in slower gastric emptying, greater feed-
ing intolerance, and, thereby, paradoxically less pro-
tein and calorie delivery.
The strengths of this study include randomisation,
comparing two different protein amounts using en-
teral nutrition, and assessment of the impact of nu-
trition provision on muscle mass and functional
outcomes that is essential for planning a larger mul-
ticentre study.
This pilot study aims to clarify whether an enteral
feeding protocol with a volume target and supple-
mental protein has potential to increase protein and
energy delivery in mechanically ventilated critically
ill patients and will provide preliminary estimates as
to whether this intervention has the capacity to
affect muscle mass or other patient-centred
outcomes.
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ADL: Activities of daily living; APACHE: Acute Physiology and Chronic Health
Evaluation; BMI: Body mass index; CONSORT: Consolidated Standards for
Reporting of Trials; ECMO: Extracorporeal membrane oxygenation;
GEE: Generalized estimating equation; HRQoL: Health-related quality of life;
IBW: Ideal body weight; ICU: Intensive care unit; ICUAW: Intensive care unit
acquired weakness; MEE: Measured using energy expenditure; MRC: Medical
Research Council; MRC-SS: Medical Research Council sum score; MUAC: Mid
Upper Arm Circumference; MV: Mechanically ventilated; PFET-s: Physical
Function in Intensive Care Test – scored; QMLT: Quadriceps muscle layer
thickness; RQ: Respiratory quotient; SD: Standard deviation; SGA: Subjective
global assessment; SOFA: Sequential Organ Failure Assessment
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